The belladonna alkaloids atropine and scopolamine are naturally occurring tertiary amine alkaloids derived from Atropa belladonna and related Solanaceae species. Their tertiary amine structure confers lipid solubility, central nervous system (CNS) penetration, and oral bioavailability, properties that shape both their therapeutic indications and their toxicity profile. Ipratropium, a quaternary derivative of atropine, was developed specifically to eliminate CNS penetration while retaining peripheral muscarinic blockade, and is the paradigm case for how structural modification of a natural product can tailor pharmacokinetics for organ-specific use.
Atropine: Structure and Blood-Brain Barrier Penetration. Atropine (dl-hyoscyamine) is a racemic mixture of d- and l-hyoscyamine, with nearly all pharmacological activity residing in the l-isomer. As a tertiary amine, atropine is un-ionized at physiological pH, crosses the blood-brain barrier (BBB) readily, and is well absorbed from the gastrointestinal (GI) tract after oral administration. Oral bioavailability is approximately 25 percent due to first-pass hepatic metabolism, while intramuscular (IM) and intravenous (IV) routes achieve reliable systemic levels within minutes. Peak plasma concentration after IV administration is reached within 2 to 3 minutes; the half-life is approximately 2 to 3 hours. Atropine is competitive at all five muscarinic receptor subtypes (M1 through M5) without meaningful subtype selectivity, making it the broadest-acting muscarinic antagonist in clinical use and the agent of first choice in situations requiring rapid, complete muscarinic blockade.1
Atropine: Clinical Indications. The clinical indications for atropine span several distinct pharmacological contexts. In cardiology and emergency medicine, atropine is a first-line agent for symptomatic bradycardia and atrioventricular (AV) block by blocking vagal M2 (muscarinic subtype 2) receptor-mediated slowing of the sinoatrial (SA) node; the standard adult dose for this indication is 0.5 to 1 mg IV, repeated every 3 to 5 minutes to a maximum of 3 mg per the Advanced Cardiac Life Support (ACLS) algorithm. As an antisialagogue (agent reducing secretions) before general anesthesia, intramuscular atropine 0.4 to 0.6 mg reduces airway secretions and prevents reflex bradycardia from airway instrumentation; glycopyrrolate has largely replaced atropine for this purpose in contemporary anesthetic practice because its quaternary structure prevents CNS adverse effects and its longer duration reduces the need for repeat dosing. For ophthalmologic use, topical atropine 1 percent produces prolonged cycloplegia and mydriasis (lasting 7 to 14 days), used for refraction in children and treatment of anterior uveitis to prevent posterior synechiae. As an antidote for organophosphate (OP) and carbamate poisoning, atropine is administered in high, rapidly escalating doses titrated to secretion drying rather than heart rate normalization, as detailed in Module 03.12
Scopolamine: Pharmacology and Motion Sickness. Scopolamine (hyoscine) is structurally similar to atropine but with an epoxide bridge that confers greater CNS penetration and more pronounced central anticholinergic effects at equivalent peripheral doses. Scopolamine produces sedation, amnesia, and antiemesis at doses that produce modest peripheral anticholinergic effects, making it pharmacologically distinct from atropine despite sharing the same receptor targets. The primary clinical application of scopolamine is prevention and treatment of motion sickness: transdermal scopolamine patches (Transderm Scop, 1.5 mg delivering approximately 1 mg over 72 hours) applied behind the ear reduce motion sickness by blocking muscarinic input to the vestibular nuclei and the vomiting center in the medullary reticular formation. The transdermal route avoids the peak-and-trough levels associated with oral dosing and maintains steady-state plasma concentrations for 3 days, making it practical for extended travel. Scopolamine is also used as a preoperative medication to produce sedation and retrograde amnesia, an application that has largely been supplanted by benzodiazepines but retains a role in selected settings. CNS adverse effects including confusion, hallucinations, and agitation are more common with scopolamine than with atropine, particularly in elderly patients, and represent a limiting factor for its use in this population.13
Ipratropium: Quaternary Structure and Airway Selectivity. Ipratropium bromide is a quaternary ammonium derivative of atropine in which quaternization of the nitrogen creates a permanent positive charge. This structural change eliminates BBB penetration and reduces GI absorption after inhalation to negligible levels (less than 1 percent systemic bioavailability via the inhaled route), making ipratropium essentially a locally acting bronchodilator with no meaningful CNS or systemic cardiovascular effects at inhaled doses. Ipratropium blocks M1 (muscarinic subtype 1), M2 (muscarinic subtype 2), and M3 (muscarinic subtype 3) muscarinic receptors in the airways; M3 blockade in bronchial smooth muscle produces bronchodilation, while M1 blockade at airway ganglia augments the bronchodilatory response. M2 receptor blockade at presynaptic nerve terminals on bronchomotor neurons has a potentially opposing effect (removal of autoinhibition of acetylcholine [ACh] release), but the net effect at clinically used doses is bronchodilation. Ipratropium is a first-line bronchodilator in chronic obstructive pulmonary disease (COPD), where parasympathetic tone contributes substantially to baseline bronchoconstriction; in asthma, it is used as an adjunct to beta-2 agonists in acute severe attacks but is not recommended as monotherapy for maintenance. Onset of bronchodilation is 15 to 30 minutes, slower than short-acting beta-2 agonists, which explains why it is combined with albuterol (as Combivent or DuoNeb) rather than used alone in acute settings.4
Atropine: tertiary, crosses BBB, non-selective M1–M5, oral/IM/IV, half-life 2–3 h; indications: bradycardia, OP antidote, preop antisialagogue, cycloplegia. Scopolamine: tertiary, greater CNS penetration than atropine, sedation + amnesia + antiemesis predominate; indications: motion sickness (transdermal), preop amnesia. Ipratropium: quaternary, no BBB penetration, inhaled only (<1% systemic), selective airway effect; indications: COPD bronchodilation, acute severe asthma adjunct. All three: contraindicated in narrow-angle glaucoma, prostatic obstruction, and obstructive GI disease.
The development of organ-selective muscarinic antagonists was driven by the recognition that non-selective agents such as atropine produce a broad spectrum of peripheral and central adverse effects that limit tolerability, particularly in elderly patients. Selectivity has been pursued through three strategies: subtype-selective receptor binding (M3 [muscarinic subtype 3] preference for bladder and airway agents), pharmacokinetic restriction to the target organ (inhaled delivery for airway agents, quaternary structure for urinary agents), and exploitation of tissue-specific receptor subtype expression patterns. No currently approved agent achieves absolute selectivity, but the therapeutic ratio for organ-specific effects has been substantially improved over atropine.
Overactive Bladder Agents: Oxybutynin and Tolterodine. Oxybutynin was the first muscarinic antagonist developed specifically for overactive bladder (OAB), and it remains the most widely used agent in this class despite its well-characterized adverse effect burden. Oxybutynin has mixed pharmacology: it is a non-selective muscarinic antagonist with additional direct smooth muscle relaxant activity and local anesthetic properties at the bladder wall. It is available as an immediate-release oral formulation, an extended-release tablet, and a transdermal patch; the transdermal and extended-release formulations reduce peak plasma concentrations and also reduce the first-pass generation of the active metabolite N-desethyloxybutynin, which is responsible for most of the anticholinergic adverse effects including dry mouth and cognitive impairment. Tolterodine is a more selective muscarinic antagonist developed as a competitive alternative to oxybutynin, with comparable bladder efficacy but lower central nervous system (CNS) penetration due to its lower lipophilicity; this difference translates to substantially lower rates of cognitive adverse effects, making it preferred over immediate-release oxybutynin in older patients. Both oxybutynin and tolterodine are metabolized by CYP2D6 (cytochrome P450 isoform 2D6) and CYP3A4 (cytochrome P450 isoform 3A4), generating interactions with potent inhibitors of these enzymes.5
Newer Bladder Antimuscarinics: Solifenacin, Darifenacin, Fesoterodine, and Trospium. The subsequent generation of overactive bladder (OAB) agents refined selectivity further. Solifenacin is an M3-preferring antimuscarinic with a long half-life (45 to 68 hours) allowing once-daily dosing; it has lower rates of dry mouth than oxybutynin and modest CNS (central nervous system) penetration that remains a clinical concern in cognitively vulnerable patients. Darifenacin has the highest M3 selectivity of any approved antimuscarinic, with approximately 9-fold selectivity for M3 over M1 (muscarinic subtype 1); this M3 selectivity is relevant because M1 receptors in the CNS mediate cognitive function, and avoiding M1 blockade in theory reduces cognitive risk. Fesoterodine is a prodrug hydrolyzed by non-specific esterases to the same active metabolite as tolterodine, offering a predictable pharmacokinetic profile independent of CYP2D6 polymorphisms; it is available in 4 mg and 8 mg doses.5
Trospium and Mirabegron. Trospium chloride is a quaternary ammonium compound that does not cross the BBB (blood-brain barrier), making it theoretically the safest OAB agent for CNS-sensitive patients including the elderly and those with dementia; it is excreted primarily unchanged in urine, creating high local bladder concentrations that may contribute to its efficacy. Mirabegron is a beta-3 adrenoceptor agonist rather than a muscarinic antagonist, included here because it is used as a first-line alternative or combination partner when antimuscarinic therapy is limited by adverse effects; its mechanism of bladder smooth muscle relaxation via beta-3 receptor activation bypasses all muscarinic adverse effects entirely, making it the preferred agent in patients where anticholinergic burden is a concern.56
Long-Acting Inhaled Antimuscarinics: Tiotropium, Aclidinium, and Umeclidinium. The recognition that ipratropium's short duration (4 to 6 hours) required four-times-daily dosing for chronic obstructive pulmonary disease (COPD) maintenance led to the development of long-acting muscarinic antagonist (LAMA) class. Tiotropium (Spiriva) was the first approved LAMA and is the most widely studied; it is administered once daily via the HandiHaler or Respimat inhaler, and remains the most comprehensively evaluated agent in the class. Tiotropium's prolonged duration is explained by its kinetic selectivity: it dissociates from M3 receptors much more slowly than from M2 (muscarinic subtype 2) receptors (M3 half-life of dissociation approximately 35 hours vs. approximately 3 hours for M2), meaning that M3-mediated bronchomotor blockade is sustained while M2 autoreceptor blockade (which could paradoxically increase ACh release) is relatively short-lived. Aclidinium is a twice-daily LAMA that undergoes rapid hydrolysis in plasma to inactive metabolites, minimizing systemic exposure and reducing the risk of systemic anticholinergic effects. Umeclidinium is a once-daily LAMA most commonly used in fixed-dose combination with the long-acting beta-2 agonist vilanterol (as Anoro Ellipta) for COPD maintenance; this combination exploits the complementary mechanisms of muscarinic bronchodilation and beta-2 adrenergic bronchodilation. All LAMAs improve lung function, reduce exacerbation frequency, and improve quality of life in COPD; they are not recommended as maintenance therapy in asthma without concurrent inhaled corticosteroids.47
GI (Gastrointestinal) Antimuscarinics and Anticholinergic Burden. Gastrointestinal antimuscarinics include dicyclomine (dicycloverine) and hyoscine butylbromide (scopolamine butylbromide). Dicyclomine is used for irritable bowel syndrome (IBS) with predominant cramping; it has mixed antimuscarinic and direct smooth muscle relaxant activity, similar to oxybutynin in its mechanism breadth. Hyoscine butylbromide (Buscopan) is a quaternary ammonium compound that does not cross the BBB, used for GI and urinary tract smooth muscle spasm; it is widely available as a GI antispasmodic in many countries and is administered IV in acute abdominal colic. The cumulative anticholinergic burden across all drug classes is quantified by tools including the Anticholinergic Cognitive Burden (ACB) scale and the Anticholinergic Risk Scale (ARS). Many commonly prescribed drugs outside the dedicated antimuscarinic class carry substantial anticholinergic burden: first-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants (amitriptyline, nortriptyline), antipsychotics (olanzapine, clozapine, quetiapine), antiarrhythmics (disopyramide), and bladder antimuscarinics together constitute the major sources of polypharmacy anticholinergic load. Accumulated anticholinergic burden has been associated with increased risk of cognitive impairment, falls, urinary retention, and all-cause mortality in older adults, making regular medication review essential in any patient prescribed multiple agents from this spectrum.6810
For patients with cognitive vulnerability or dementia: trospium (quaternary, no CNS penetration) or mirabegron (beta-3 agonist, zero anticholinergic burden) are preferred. For patients on complex CYP2D6/3A4 polypharmacy: fesoterodine (non-CYP hydrolysis to active metabolite) avoids pharmacokinetic interactions. For maximum M3 selectivity: darifenacin. For once-daily convenience with acceptable tolerability: solifenacin. When any antimuscarinic is poorly tolerated: switch to mirabegron before escalating dose. Review all other medications for additive anticholinergic burden using ACB or ARS scale at every clinical encounter.
The central nervous system (CNS)-penetrating muscarinic antagonists exploit cholinergic-dopaminergic imbalance in the striatum to treat movement disorders, and exploit muscarinic input to brainstem vestibular and emetic circuits to treat motion sickness. The same CNS penetration that confers these therapeutic effects also produces dose-dependent cognitive adverse effects that are amplified in elderly patients, in those with pre-existing cognitive impairment, and in patients who carry a high cumulative anticholinergic burden from other medications.
Benztropine and Trihexyphenidyl in Parkinson Disease. In the striatum, dopaminergic neurons from the substantia nigra pars compacta normally inhibit cholinergic interneurons, maintaining a balance between dopaminergic and cholinergic tone. In Parkinson disease (PD), the loss of nigrostriatal dopaminergic input unmasks relative cholinergic overactivity, contributing to the tremor and rigidity components of the motor syndrome. Benztropine mesylate and trihexyphenidyl are tertiary amine muscarinic antagonists that penetrate the blood-brain barrier (BBB) and preferentially block M1 (muscarinic subtype 1) and M4 (muscarinic subtype 4) receptors in the striatum, reducing cholinergic interneuron activity and partially restoring the dopaminergic-cholinergic balance. Their therapeutic niche in PD is narrow: they are most effective for tremor and least effective for bradykinesia and postural instability, and they have been largely supplanted by levodopa and dopamine agonists as first-line therapy. Current guidelines recommend against their use in elderly patients with PD (generally defined as those older than 70 years) because the CNS anticholinergic adverse effects, including confusion, memory impairment, hallucinations, and delirium, are poorly tolerated and difficult to distinguish clinically from PD-related cognitive decline. They retain a role as second-line agents for tremor in younger patients with PD whose tremor is not adequately controlled by dopaminergic therapy.9
Drug-Induced Extrapyramidal Symptoms. Drug-induced extrapyramidal symptoms (EPS) produced by dopamine D2 (dopamine receptor subtype 2)-blocking antipsychotics and antiemetics (haloperidol, metoclopramide, prochlorperazine) include acute dystonia, parkinsonism, and akathisia (motor restlessness). Benztropine 1 to 2 mg intramuscularly (IM) or IV is first-line treatment for acute dystonic reactions, producing rapid resolution of torticollis, oculogyric crisis, and laryngospasm within 5 to 15 minutes of parenteral administration; diphenhydramine 50 mg IM or IV is an acceptable alternative because its anticholinergic action, though incidental to its intended antihistamine role, is sufficient to reverse acute dystonia. For drug-induced parkinsonism in patients receiving ongoing antipsychotic therapy, oral benztropine or trihexyphenidyl is used prophylactically or as needed; however, the preferred strategy where clinically feasible is to reduce the antipsychotic dose, switch to an atypical agent with lower D2 affinity, or switch to an antipsychotic with intrinsic muscarinic antagonist activity (such as clozapine or quetiapine, which rarely cause EPS because their anticholinergic properties offset the dopaminergic blockade). Anticholinergic drugs do not reliably treat akathisia, for which beta-blockers (propranolol) or benzodiazepines are preferred.9
Anticholinergic Burden and Cognitive Risk in Older Adults. The Anticholinergic Cognitive Burden (ACB) scale assigns scores of 1 (possible anticholinergic activity) or 2 to 3 (definite anticholinergic activity) to individual drugs, and the cumulative score correlates with risk of cognitive impairment and dementia. A landmark prospective cohort study by Gray and colleagues found that total standardized daily doses of anticholinergic medications were associated with a significantly increased risk of dementia, with the association persisting after controlling for confounders and being most pronounced for urological antimuscarinics and first-generation antihistamines. The mechanism involves progressive muscarinic M1 receptor blockade in the hippocampus, prefrontal cortex, and basal forebrain circuits that mediate learning and memory encoding. In patients already carrying a diagnosis of Alzheimer disease (AD) who are receiving AChE inhibitors, the co-prescription of any drug with significant anticholinergic burden directly opposes the intended pharmacological effect of the AChE inhibitor and should be avoided. This is a common clinical problem because the same patient cohort that receives AChE inhibitors (elderly, multiple comorbidities) is also at greatest risk of receiving bladder antimuscarinics, first-generation antihistamines for sleep, and tricyclic antidepressants for pain or depression. Systematic deprescribing of anticholinergic medications is associated with cognitive improvement and reduced falls risk in older adults.811
High ACB score drugs to deprescribe or avoid in patients over 65: first-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants (amitriptyline, doxepin), bladder antimuscarinics (oxybutynin IR, tolterodine), antipsychotics with high anticholinergic burden (olanzapine, clozapine), antiparkinsonian anticholinergics (benztropine, trihexyphenidyl), antiemetics (prochlorperazine, promethazine). When AChE inhibitor therapy for AD is initiated: systematically review and eliminate all high-ACB medications. Prefer trospium or mirabegron for OAB; prefer second-generation antihistamines (cetirizine, loratadine) for allergy; prefer SSRIs for depression.
The anticholinergic toxidrome results from competitive muscarinic receptor blockade at all end-organ sites simultaneously: the heart, exocrine glands, smooth muscle of the gastrointestinal (GI) tract and urinary bladder, the eye, and the central nervous system (CNS). The mnemonic "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter" encodes the cardinal features and remains the most clinically useful memory aid for rapid bedside recognition. Distinguishing the anticholinergic from the cholinergic toxidrome is a high-stakes emergency diagnosis because their treatments are diametrically opposed.
Clinical Features and the Mnemonic. The anticholinergic toxidrome produces a predictable constellation arising from the loss of muscarinic-mediated physiological functions. "Hot as a hare" refers to hyperthermia secondary to anhidrosis (inability to sweat): eccrine sweat glands are cholinergically innervated, and their blockade abolishes the primary heat dissipation mechanism, leading to hyperthermia that can reach dangerous levels in a warm environment. "Dry as a bone" refers to dry mucous membranes and skin from blockade of salivary, lacrimal, bronchial, and sweat gland secretions. "Red as a beet" refers to cutaneous flushing from peripheral vasodilation, which represents compensatory heat dissipation through the only remaining mechanism after sweat gland failure. "Blind as a bat" refers to mydriasis (pupillary dilation from loss of M3 [muscarinic subtype 3] pupilloconstrictor tone) and cycloplegia (loss of accommodation from ciliary muscle paralysis), producing blurred near vision that can be disabling. "Mad as a hatter" refers to the CNS manifestations: agitation, confusion, disorientation, hallucinations (typically visual and tactile rather than auditory), and in severe toxicity, seizures and coma. Additional features include tachycardia (loss of M2 vagal slowing), urinary retention (loss of detrusor M3 tone with preservation of internal urethral sphincter sympathetic tone), ileus (loss of GI M3 motility), and decreased bowel sounds.12
Severity Grading and Causative Agents. Anticholinergic toxicity is commonly graded in three tiers. Mild toxicity (grade 1) presents with dry mouth, tachycardia, mydriasis, urinary retention, and decreased bowel sounds without CNS or thermoregulatory involvement; this grade is frequently seen as a predictable adverse effect of therapeutic doses of antihistamines, bladder antimuscarinics, or tricyclic antidepressants (TCAs). Moderate toxicity (grade 2) adds agitation, confusion, and disorientation, with mild hyperthermia and flushing; this grade typically occurs with overdose of the same agents. Severe toxicity (grade 3) produces hyperthermia exceeding 40 degrees Celsius, seizures, coma, and cardiovascular instability; at this grade the diagnosis is an acute emergency. Common causative drug classes include diphenhydramine and other first-generation antihistamines (the leading cause in pediatric anticholinergic poisoning), tricyclic antidepressant (TCA) overdose (where sodium channel blockade adds QRS-complex (the electrocardiographic ventricular depolarization complex) prolongation and ventricular arrhythmias to the anticholinergic picture), antipsychotic overdose, scopolamine, jimsonweed (Datura stramonium, which contains atropine, scopolamine, and hyoscyamine as active alkaloids), and combination products containing antihistamine plus decongestant or analgesic.12
Management and Physostigmine Reversal. Management of anticholinergic toxicity is primarily supportive: benzodiazepines for agitation and seizures, active external cooling for hyperthermia, urinary catheterization for retention, and cardiac monitoring. Physostigmine salicylate, the only CNS-penetrating AChE inhibitor in clinical use (see Module 02), is the specific antidote for central anticholinergic toxicity. By inhibiting central AChE, physostigmine raises ACh levels at CNS muscarinic M1 (subtype 1) receptors, reversing delirium, agitation, and hallucinations with a typical onset of 2 to 5 minutes after IV administration. The standard adult dose is 0.5 to 2.0 mg IV given slowly over 5 minutes; the duration of effect is 30 to 60 minutes (shorter than the duration of most anticholinergic agents), so repeat dosing may be needed. Physostigmine carries critical contraindications that must be excluded before administration: TCA overdose is an absolute contraindication because physostigmine in the setting of TCA-mediated sodium channel blockade has caused seizures and fatal bradyasystole; QRS prolongation on the electrocardiogram (ECG) is therefore a hard stop before physostigmine use. Reactive airways disease, mechanical bowel obstruction, and known cardiac conduction disease are relative contraindications. Glycopyrrolate should be immediately available to reverse cholinergic excess if physostigmine produces bradycardia or bronchospasm.12
Anticholinergic: hot, dry, flushed, mydriasis, tachycardia, urinary retention, ileus, agitation/hallucinations, absent bowel sounds. Cholinergic (SLUDGE/DUMBELS): wet, diaphoretic, miosis, bradycardia, urinary/fecal incontinence, bronchospasm, bronchorrhea, fasciculations, seizures. Critical distinction: skin moisture. Anticholinergic patients are dry; cholinergic patients are wet. Pupil size: anticholinergic produces mydriasis; cholinergic produces miosis. Treatment is opposite: physostigmine for anticholinergic toxidrome; atropine + 2-PAM + benzodiazepines for cholinergic toxidrome. Physostigmine is contraindicated in TCA overdose (check ECG for QRS prolongation first).
Autonomic dysfunction encompasses a spectrum of disorders in which the reflex mechanisms that normally maintain cardiovascular homeostasis during postural change are impaired. These disorders were deferred from the autonomic nervous system (ANS) pharmacology series for standalone treatment here because their pharmacological management draws on principles from across the autonomic pharmacology series: adrenergic agonists, mineralocorticoids, norepinephrine precursors, and beta-adrenoceptor antagonists are all deployed depending on the underlying mechanism and severity. Understanding the pathophysiology of each syndrome is prerequisite to selecting appropriate therapy.
Orthostatic Hypotension: Definition and Mechanisms. Orthostatic hypotension (OH) is defined as a sustained reduction in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing from a supine or seated position. This hemodynamic change is normally prevented by the baroreflex arc: gravitational pooling of blood in the lower extremities on standing is sensed by arterial baroreceptors in the carotid sinus and aortic arch, triggering reflex sympathetic activation that increases heart rate, cardiac contractility, and peripheral vascular resistance, restoring cerebral perfusion within seconds. In neurogenic OH, the afferent limb (baroreceptor sensing), central processing (brainstem and spinal cord pathways), or efferent limb (sympathetic postganglionic neurons to the heart and blood vessels) of this arc is damaged or dysfunctional. Non-neurogenic OH arises from volume depletion, medication effects (antihypertensives, diuretics, vasodilators, tricyclic antidepressants [TCAs], antipsychotics), or cardiac pump dysfunction and is distinguished from neurogenic OH by the preservation of compensatory tachycardia on standing in non-neurogenic cases. Symptomatic OH produces lightheadedness, presyncope, syncope, visual dimming, and coat-hanger headache (nuchal and shoulder pain from ischemia of postural neck muscles), which are characteristically worse after meals, in the morning, in warm environments, and after exercise.14
Neurogenic Orthostatic Hypotension: Causes and Initial Management. The most common causes of neurogenic OH include multiple system atrophy (MSA), Parkinson disease (PD) with autonomic involvement, pure autonomic failure (PAF), and diabetic autonomic neuropathy. In MSA and PAF, preganglionic and postganglionic sympathetic neurons are lost, respectively, producing severe OH that is resistant to non-pharmacological measures. Non-pharmacological interventions should always precede or accompany drug therapy: graduated compression stockings (waist-high, 20 to 40 mmHg) reduce venous pooling; abdominal binders augment venous return; head-of-bed elevation (10 to 20 degrees) reduces nocturnal supine hypertension while improving morning orthostatism; increased dietary salt (10 g per day) and fluid intake (2 to 3 liters per day) expand plasma volume; small frequent meals reduce post-prandial OH by distributing splanchnic blood flow demands. Avoidance of precipitating factors (prolonged standing, heat, alcohol, large carbohydrate meals) is equally important.1415
Pharmacological Management of Neurogenic OH. Fludrocortisone is a synthetic mineralocorticoid that increases renal sodium and water retention, expanding plasma volume and enhancing pressor responsiveness. It is typically started at 0.1 mg orally once daily and titrated to 0.1 to 0.3 mg daily; adverse effects include supine hypertension, hypokalemia, and peripheral edema, all reflecting its mineralocorticoid activity. Midodrine is a prodrug converted by peripheral tissue esterases to desglymidodrine, an alpha-1 adrenoceptor agonist that constricts peripheral arterioles and venous capacitance vessels, raising standing blood pressure without crossing the BBB (blood-brain barrier). The standard dose is 2.5 to 10 mg orally three times daily, taken before activities requiring standing; the last dose should be no later than 4 to 6 hours before bedtime to avoid supine hypertension during sleep. Droxidopa (L-threo-3,4-dihydroxyphenylserine, L-DOPS) is a synthetic precursor of norepinephrine that is converted by aromatic l-amino acid decarboxylase (AADC) to norepinephrine directly within sympathetic nerve terminals and peripheral tissues. Unlike midodrine, droxidopa can produce central norepinephrine elevation as well as peripheral, but its primary value is in neurogenic OH where sympathetic nerve terminals are still present but norepinephrine synthesis is deficient, as in dopamine beta-hydroxylase deficiency and some cases of PD. Droxidopa is dosed at 100 mg to 600 mg orally three times daily.15
Postural Orthostatic Tachycardia Syndrome (POTS). Postural orthostatic tachycardia syndrome (POTS) is defined as a heart rate increase of 30 beats per minute or more (40 bpm or more in patients aged 12 to 19 years) within 10 minutes of standing, in the absence of orthostatic hypotension, accompanied by symptoms of orthostatic intolerance. POTS is pathophysiologically distinct from neurogenic OH: blood pressure is generally maintained on standing, but the compensatory tachycardia is exaggerated, reflecting either hypovolemia with excessive reflex tachycardia, partial dysautonomia with selective sympathetic denervation of the lower limbs (hyperadrenergic POTS), or impaired norepinephrine reuptake. Non-pharmacological management includes volume expansion (increased salt and fluid intake), compression garments, physical deconditioning reversal through graded exercise, and avoidance of prolonged standing. Pharmacologically, low-dose beta-blockers (propranolol 10 to 20 mg twice daily) reduce the excessive tachycardia by blocking cardiac beta-1 receptors, and are among the most commonly prescribed agents for POTS; they must be used cautiously in the hyperadrenergic subtype because blockade of peripheral beta-2 vasodilator receptors in the setting of elevated catecholamines can paradoxically worsen hypertension. Ivabradine, a selective I-f current (funny current) blocker that reduces sinoatrial (SA) node firing rate without affecting contractility or blood pressure, has been used as an alternative heart rate-lowering agent in POTS when beta-blocker adverse effects are limiting.16
Diabetic Autonomic Neuropathy. Diabetic autonomic neuropathy (DAN) is a common and underdiagnosed complication of long-standing diabetes mellitus (DM), affecting both sympathetic and parasympathetic divisions. Cardiovascular manifestations include resting tachycardia (loss of vagal tone), exercise intolerance, silent myocardial ischemia (loss of pain sensation from cardiac sympathetic afferents), and orthostatic hypotension from postganglionic sympathetic vasomotor denervation. Gastrointestinal (GI) manifestations include gastroparesis (delayed gastric emptying from vagal efferent damage, producing early satiety, nausea, and erratic postprandial glycemia), constipation (colonic dysmotility), and diarrhea (small bowel dysmotility with bacterial overgrowth). Genitourinary manifestations include neurogenic bladder (initially reduced bladder sensation with large residual volumes, progressing to overflow incontinence) and erectile dysfunction. Sudomotor dysfunction produces anhidrosis of the lower extremities with compensatory hyperhidrosis of the upper body. Management of DAN is primarily directed at glycemic control to prevent progression, supplemented by symptom-specific pharmacotherapy: metoclopramide or domperidone for gastroparesis (prokinetics), midodrine or fludrocortisone for OH as detailed above, and alpha-1 blockers or intermittent self-catheterization for neurogenic bladder depending on detrusor vs. outlet dysfunction. Recognition of DAN in a diabetic patient should trigger comprehensive autonomic evaluation and intensification of risk factor management including glycemic control, blood pressure treatment, and lipid management.1317
Neurogenic OH (MSA, PD, PAF): fludrocortisone 0.1–0.3 mg daily (plasma volume expansion) + midodrine 2.5–10 mg TID before activities (alpha-1 agonist, avoid at bedtime) + droxidopa 100–600 mg TID (norepinephrine precursor, useful where sympathetic terminals intact). POTS: propranolol 10–20 mg BID (rate control) or ivabradine (I-f blocker, avoids hypotension); compression garments + volume expansion first. Diabetic OH: same as neurogenic OH; compress garments + sodium/fluid loading. All neurogenic OH: non-pharmacological measures first; head-of-bed elevation, compression, salt loading. Monitor for and minimize supine hypertension with all vasopressor agents. Deferred autonomic dysfunction flag: this section satisfies the deferral from ANS Chapter 6.
Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219-233.
doi:10.1111/j.1474-8673.2006.00368.xEddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607.
doi:10.1016/S0140-6736(07)61202-1Nachum Z, Shahal B, Shupak A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther. 2001;296(1):121-125.
doi:10.1124/jpet.296.1.121Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
doi:10.1056/NEJMoa0805800Chapple CR, Cardozo L, Steers W, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006;60(8):959-966.
doi:10.1111/j.1742-1241.2006.01067.xKhullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283-295.
doi:10.1016/j.eururo.2012.10.016Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia GE, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients. COPD. 2012;9(2):90-101.
doi:10.3109/15412555.2012.661492Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407.
doi:10.1001/jamainternmed.2014.7663Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes. Neurology. 2013;81(5):463-469.
doi:10.1212/WNL.0b013e31829d86b6Salahudeen MS, Nishtala PS. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharm J. 2017;25(2):165-175.
doi:10.1016/j.jsps.2016.07.002Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513.
doi:10.1001/archinternmed.2007.106Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179-184.
doi:10.1007/s13181-014-0452-xBurns TM, Mauermann ML. The evaluation of polyneuropathies. Neurology. 2011;76(7 Suppl 2):S6-S13.
doi:10.1212/WNL.0b013e31820c3622Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161(1-2):46-48.
doi:10.1016/j.autneu.2011.02.004Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287-297.
doi:10.1002/ana.24877Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-e63.
doi:10.1016/j.hrthm.2015.03.029Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579.
doi:10.2337/diacare.26.5.1553